GSK-204471

Study Sponsor: GSK

Study Title

A multi-centre, open label, single arm, 32-week treatment study in subjects with severe eosinophilic asthma not optimally controlled with current omalizumab treatment who are switched from omalizumab to mepolizumab 100mg subcutaneous (study number 204471- the OSMO study)

Medicine or Vaccine (generic name)

mepolizumab

Sponsor Identification Number

204471

Trial Registry Identification Number(#'s)

NCT02654145 2015-003697-32

Medical Condition

Asthma

Phase

Phase 4

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=204471

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT02654145

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2015-003697-32

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

An annotated case report form is not available for this study. A blank case report form will be provided. This study is available in CDISC format.

Date Added to this Site

June 2019